Surgical Innovations (GB:SUN)
LSE:SUN
Want to see GB:SUN full AI Analyst Report?
Top Page
Surgical Innovations
(LSE:SUN)
Select Model
Select Model
Rating:51Neutral
Price Target:
0.45 p
▲(0.44% Upside)
Action:ReiteratedDate:04/23/26
The score is driven primarily by mixed financial performance: low leverage and improved 2025 free cash flow are positives, but revenue softness and ongoing net losses cap the rating. Technicals are neutral-to-weak with price below longer-term averages and slightly negative MACD, while valuation is constrained by a negative P/E and no stated dividend yield.
Positive Factors
Low Leverage
A very low debt-to-equity (~0.09 in 2025) and materially reduced total debt give the company financial resilience. This conservatism preserves flexibility to fund product development, withstand procedure-volume shocks, or support working capital without forcing dilutive financing in the near term.
Negative Factors
Revenue Weakness
Sustained flat-to-declining top-line (2025 down ~2.6%) undermines operating leverage and constrains reinvestment capacity. Over multiple years this trend may reflect pricing pressure, competitive displacement, or weaker procedure volumes, all of which hinder durable margin expansion and scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A very low debt-to-equity (~0.09 in 2025) and materially reduced total debt give the company financial resilience. This conservatism preserves flexibility to fund product development, withstand procedure-volume shocks, or support working capital without forcing dilutive financing in the near term.
Read all positive factors
Surgical Innovations (SUN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£4.20M
Dividend YieldN/A
Average Volume (3M)179.78K
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue Growth-2.87%
EPS Growth52.38%
CountryUK
Employees80
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding932,816,160
10 Day Avg. Volume43,249
30 Day Avg. Volume179,777
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.55
Price to Sales (P/S)0.36
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Surgical Innovations Business Overview & Revenue Model
Company Description
Surgical Innovations Group plc, together with its subsidiaries, designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the Un...
How the Company Makes Money
SUN primarily generates revenue by selling its surgical devices and instruments to healthcare providers and through medical device distribution channels. Key revenue streams typically include: (1) sales of proprietary minimally invasive surgical i...
Surgical Innovations Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
56
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.60M | 11.95M | 12.01M | 11.34M | 9.13M |
| Gross Profit | 3.05M | 3.44M | 3.45M | 3.92M | 3.13M |
| EBITDA | -73.00K | -99.00K | 161.00K | 628.00K | 247.00K |
| Net Income | -895.00K | -1.94M | -509.00K | 264.00K | -456.00K |
Balance Sheet | |||||
| Total Assets | 11.64M | 12.24M | 14.32M | 15.60M | 15.72M |
| Cash, Cash Equivalents and Short-Term Investments | 813.00K | 195.00K | 1.21M | 2.20M | 3.64M |
| Total Debt | 665.00K | 1.24M | 1.66M | 2.16M | 2.79M |
| Total Liabilities | 4.00M | 3.70M | 3.84M | 4.63M | 5.05M |
| Stockholders Equity | 7.65M | 8.54M | 10.48M | 10.96M | 10.66M |
Cash Flow | |||||
| Free Cash Flow | 508.00K | -409.00K | -288.00K | -592.00K | -1.09M |
| Operating Cash Flow | 569.00K | -74.00K | 400.00K | 486.00K | -433.00K |
| Investing Cash Flow | -227.00K | -335.00K | -688.00K | -1.08M | -657.00K |
| Financing Cash Flow | 271.00K | -626.00K | -672.00K | -935.00K | -532.00K |
Surgical Innovations Technical Analysis
Negative
0.45
Price Trends
0.45
Positive
0.47
Negative
0.56
Negative
Market Momentum
>-0.01
Negative
<0.01
Positive
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SUN, the sentiment is Negative. The current price of 0.45 is above the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.45, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at <0.01 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SUN.
Surgical Innovations Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £9.88B | 22.64 | 11.79% | 2.35% | 2.84% | 47.82% | |
58 Neutral | £546.42M | 47.21 | 3.87% | 1.25% | 28.96% | 39.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £4.20M | -4.69 | -16.78% | ― | -2.87% | 52.38% | |
48 Neutral | £50.01M | 0.83 | 32.72% | ― | ― | ― |
* Healthcare Sector Average
GB:SUN
Surgical Innovations
0.45
-0.10
-18.18%
GB:AMS
Advanced Medical Solutions
251.00
69.31
38.15%
GB:CREO
Creo Medical
12.13
1.51
14.17%
GB:SN
Smith & Nephew
1,182.00
207.07
21.24%
GB:TSP
TruSpine Technologies Plc
―
―
―
Surgical Innovations Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Surgical Innovations Holds Revenue Steady and Boosts Margins as It Primes for Growth in 2026
Neutral
Apr 21, 2026
Surgical Innovations reported broadly flat 2025 revenues of £11.6m, with SI-branded sales down due to U.S. tariffs and challenges in India, partly offset by a 23% rise in European sales and 14% growth in UK distribution revenues. Underlying g...
Business Operations and StrategyFinancial Disclosures
Surgical Innovations Sets Date for 2025 Results and Investor Briefing
Neutral
Apr 9, 2026
Surgical Innovations Group, a UK-based medical technology company, specialises in designing, manufacturing and distributing devices for minimally invasive surgery, including branded port access systems, surgical instruments and retraction devices....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.